Float Short %

0.36

Margin Of Safety %

Put/Call OI Ratio

0.07

EPS Next Q Diff

EPS Last/This Y

0.1

EPS This/Next Y

-0.08

Price

2.44

Target Price

5.4

Analyst Recom

Performance Q

185.91

Relative Volume

4.86

Beta

1.12

Ticker: IMAB

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-05-08	IMAB	0.8763	0.00	0.00	533
2025-05-09	IMAB	0.8527	N/A	N/A	0
2025-05-12	IMAB	0.9449	N/A	N/A	0
2025-05-13	IMAB	0.912	N/A	N/A	0
2025-05-14	IMAB	0.8914	N/A	N/A	0
2025-05-15	IMAB	0.8875	N/A	N/A	0
2025-05-16	IMAB	0.8959	N/A	N/A	0
2025-05-19	IMAB	0.9109	0.00	0.00	323
2025-05-20	IMAB	0.9134	0.00	0.00	226
2025-05-21	IMAB	0.94	0.00	0.00	226
2025-05-22	IMAB	1.06	0.00	0.00	266
2025-05-23	IMAB	0.9899	0.00	0.00	266
2025-05-27	IMAB	1.04	0.00	0.00	298
2025-05-28	IMAB	1.18	0.00	0.00	308
2025-05-29	IMAB	1.28	0.00	0.00	355
2025-05-30	IMAB	1.31	0.00	0.00	385
2025-06-02	IMAB	1.28	0.00	0.00	385
2025-06-03	IMAB	1.88	0.00	0.13	411
2025-06-04	IMAB	1.79	0.07	0.13	693
2025-06-05	IMAB	2.22	0.08	0.02	643
2025-06-06	IMAB	2.45	0.07	0.01	807
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-05-08	IMAB	0.84	-	-	-0.28
2025-05-09	IMAB	0.88	-	-	-0.28
2025-05-12	IMAB	0.94	-	-	-0.28
2025-05-13	IMAB	0.92	-	-	-0.28
2025-05-14	IMAB	0.89	-	-	-0.28
2025-05-15	IMAB	0.89	-	-	-0.28
2025-05-16	IMAB	0.90	-	-	-0.28
2025-05-19	IMAB	0.91	-	-	-0.17
2025-05-20	IMAB	0.91	-	-	-0.17
2025-05-21	IMAB	0.94	-	-	-0.17
2025-05-22	IMAB	1.05	-	-	-0.17
2025-05-23	IMAB	1.05	-	-	-0.17
2025-05-27	IMAB	1.04	-	-	-0.17
2025-05-28	IMAB	1.17	-	-	-0.17
2025-05-29	IMAB	1.26	-	-	-0.17
2025-05-30	IMAB	1.31	-	-	-0.17
2025-06-02	IMAB	1.29	-	-	-0.17
2025-06-03	IMAB	1.87	-	-	-0.17
2025-06-04	IMAB	1.79	-	-	-0.17
2025-06-05	IMAB	2.29	-	-	-0.17
2025-06-06	IMAB	2.44	-	-	-0.17
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-05-08	IMAB	0.00	-20.14	0.54
2025-05-09	IMAB	0.00	-20.14	0.54
2025-05-12	IMAB	0.00	-20.15	0.34
2025-05-13	IMAB	0.00	-20.15	0.34
2025-05-14	IMAB	0.00	-20.15	0.34
2025-05-15	IMAB	0.00	-20.15	0.34
2025-05-16	IMAB	0.00	-20.15	0.34
2025-05-19	IMAB	0.00	-19.28	0.34
2025-05-20	IMAB	0.00	-19.28	0.34
2025-05-21	IMAB	0.00	-19.28	0.34
2025-05-22	IMAB	0.00	-19.28	0.34
2025-05-23	IMAB	0.00	-19.28	0.34
2025-05-27	IMAB	0.00	-44.03	0.34
2025-05-28	IMAB	0.00	-44.03	0.36
2025-05-29	IMAB	0.00	-44.03	0.36
2025-05-30	IMAB	0.00	-44.03	0.36
2025-06-02	IMAB	0.00	-44.03	0.36
2025-06-03	IMAB	0.00	-44.03	0.36
2025-06-04	IMAB	0.00	-44.03	0.36
2025-06-05	IMAB	0.00	-44.03	0.36
2025-06-06	IMAB	0.00	-44.03	0.36
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.04

Avg. EPS Est. Next Quarter

-0.04

Insider Transactions

Institutional Transactions

-44.03

Beta

1.12

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

97.1

Max Drawdown 5-Year %

-99.3

Target Price

5.4

P/E

Forward P/E

PEG

P/S

P/B

1.01

P/Free Cash Flow

EPS

-0.71

Average EPS Est. Cur. Y

-0.17

EPS Next Y. (Est.)

-0.26

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

4.86

Return on Equity vs Sector %

-28.6

Return on Equity vs Industry %

-10.6

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.11

EBIT Estimation

I-MAB

Sector: Healthcare

Industry: Biotechnology

Employees: 32

I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

stock quote shares IMAB – I-Mab ADR Stock Price stock today

news today IMAB – I-Mab ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch IMAB – I-Mab ADR yahoo finance google finance

stock history IMAB – I-Mab ADR invest stock market

stock prices IMAB premarket after hours

ticker IMAB fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: IMAB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y